• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Momenta Pharmaceuticals Inc. (MNTA)

    -NasdaqGS
    11.14 Up 0.24(2.20%) May 27, 4:00PM EDT
    |After Hours : 11.14 Up 0.00 (0.02%) May 27, 4:25PM EDT
    ProfileGet Profile for:
    Momenta Pharmaceuticals Inc.
    675 West Kendall Street
    Cambridge, MA 02142
    United States - Map
    Phone: 617-491-9700
    Website: http://www.momentapharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:258

    Business Summary 

    Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is used to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and M356, a generic product candidate for three-times-weekly COPAXONE. Its biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis; M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis; and other biosimilar programs. The company’s novel therapeutics programs include Necuparanib, a novel oncology product candidate derived from heparin; Anti-FcRn program for acute and chronic/intermittent therapies in a range of autoantibody driven diseases; SIF3 program, a novel recombinant protein containing three IgG Fc regions to maximize activity; and hsIVIg, a hyper-sialylated version of intravenous immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura, Kawasaki disease, and chronic inflammatory demyelinating polyneuropathy. It has collaboration and license agreements with Sandoz AG and Mylan Ireland Limited, as well as Baxalta U.S. Inc., Baxalta GmbH, and Baxalta Incorporated. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Momenta Pharmaceuticals Inc.

    Corporate Governance 
    Momenta Pharmaceuticals Inc.’s ISS Governance QuickScore as of May 1, 2016 is 5. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 8; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Craig A. Wheeler , 56
    Chief Exec. Officer, Pres and Exec. Director
    1.23M1.72M
    Dr. Ganesh Venkataraman Kaundinya Ph.D., 49
    Co-Founder, Chief Scientific Officer and Sr. VP of Research
    633.00K0.00
    Mr. Richard P. Shea , 64
    Chief Financial Officer, Sr. VP and Treasurer
    579.00K63.00K
    Mr. Bruce A. Leicher J.D., 60
    Sr. VP, Gen. Counsel and Corp. Sec.
    605.00K586.00K
    Dr. James M. Roach M.D., 56
    Chief Medical Officer and Sr. VP of Devel.
    643.00K1.33M
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders